Although the clinical efficacy of oncolytic viruses has been demonstrated for local treatment, the ability to induce immune-mediated regression of distant metastases is still poorly documented. We here report that an engineered oncolytic Vaccinia Virus, VV WR TK -RR --FCU1, is able to induce an immunogenic cell death and thus to generate a systemic immune response. Effect on tumor growth and survival is largely driven by CD8 + T-cells, and we could demonstrate that the immune cell infiltrate in the tumor could be reprogrammed towards a higher ratio of effector T-cells to regulatory CD4 + T-cells. The key role of the type 1-IFN pathway in oncolytic virotherapy was also highlighted, and we could show a strong abscopal response in Ifnar -/-tumors. In this model, the single administration of the virus directly into the tumors, on one flank, led to a regression in the contralateral flank (i.e. opposite to the virus injection site). Moreover, we observed that these effects were further enhanced when the oncolytic treatment is combined with either immunogenic chemotherapy such as oxaliplatin, or with immune checkpoint blockers (ICB) such as anti-PD-1 or anti-CTLA-4. Altogether, these data suggest that local oncolytic virotherapy combined with ICB would best benefit patients harboring tumors altered in IFNAR signaling.
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Vaccinia Virus : VV WR TK -RR --FCU1
Vaccinia virus is a double strand DNA virus that replicates strictly in cytoplasm : no risk of nuclear integration Large DNA insertions are possible (up to 25 kb) as several expression cassettes: enzymes, cytokines, antibodies, … have been successfully vectorized Western Reserve strain: adapted to murine cell replication used as surrogate oncolytic vaccinia virus for in vivo preclinical studies Thymidine kinase (TK) and Ribonucleotide Reductase (RR) double deleted restrict replication of vaccinia virus to proliferative cells (tumor cells): safer than WT vaccinia virus ABSTRACT RESULTS WT cells on the opposite flank. When MCA205 Ifnar -/-tumors reached approximately 20 mm², mice were intratumorally treated with 10 7 pfu WR on day 0 and day 3. Mice were administrated with 250 µg/mouse anti-PD-1 mAb (at day 6, 9 and 12), with 100 µg/mouse anti-CTLA4 mAb (at day 6, 9 and 12), or with 10 mg/kg/mouse oxaliplatin (at day 6). Tumor sizes in the ipsilateral (treated,B) or contralateral (untreated, C) are shown as means ± SEM. The experiments have been performed twice with similar results. *** p < 0.001; ** p < 0.01; * p < 0.05 by Kruskal-Wallis test followed by Dunn's post test VV WR -TK -RR --Fcu1, a surrogate model for the preclinical study of TG6002, a first-in class oncolytic virus, induce immunogenic cell death and generate a systemic immune response VV is able to reprogram immune cell infiltrate within the tumor microenvironment towards a higher ratio of cytotoxic T cells to regulatory T cells Oncolytic Virus alone or in combination with oxaliplatin or immune check point blockers, produces abscopal effects on distant untreated tumors, particularly when the treated tumor displays attenuated type I IFN signaling These preclinical data further strengthen the preclinical data package of Transgene's most advanced next generation oncolytic virus TG6002 TG6002 is due to enter the clinic in H1 2017 in patients with recurrent glioblastoma
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